In light of previous work (Varhaug et al., 2017; Leurs et al., 2017), we cannot exclude the possibility that ccf-mtDNA levels rise in-life in response to the onset of disease and then reduce as neurodegeneration increases, however longitudinal assessments in PMS cases would be needed to assess this. This evidence concerns the gene PITX1 and premenstrual tension.